ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib)
April 29, 2021Alphamab Oncology announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to evaluate the efficacy and safety of KN046 in combination with Inlyta® (axitinib) for the first-line treatment of NSCLC. -
Alphamab Oncology Presented Clinical Data of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at AACR 2021
April 13, 2021Alphamab Oncology announced that data from phase Ib/II clinical study (clinical trial No.: KN046-203) of PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel for the treatment of patients with metastatic triple-negative breast ...
Pharma Sources Insight January 2025
